[Antidotes and medicines used to treat poisoning in Brazil: needs, availability and opportunities].
暂无分享,去创建一个
Tais F Galvão | Fabio Bucaretchi | Eduardo M De Capitani | Maurício G Pereira | Marcus T Silva | E. D. De Capitani | M. Silva | T. Galvão | M. G. Pereira | F. Bucaretchi
[1] Edgar Hernández-Leiva. Epidemiología del síndrome coronario agudo y la insuficiencia cardiaca en Latinoamérica , 2011 .
[2] D. Spyker,et al. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report , 2011, Clinical toxicology.
[3] Carlos Alberto Silva,et al. Impact of a poison control center on the length of hospital stay of poisoned patients: retrospective cohort. , 2011, Sao Paulo medical journal = Revista paulista de medicina.
[4] C. Smollin. Toxicology: pearls and pitfalls in the use of antidotes. , 2010, Emergency medicine clinics of North America.
[5] G. C. Rodgers,et al. Antidotes and Treatments for Chemical Warfare/Terrorism Agents: An Evidence‐Based Review , 2010, Clinical pharmacology and therapeutics.
[6] K. Kehe,et al. Development of antidotes: problems and strategies. , 2007, Toxicology.
[7] J. Bussières,et al. Antidote availability in Quebec hospital pharmacies: impact of N-acetylcysteine and naloxone consumption. , 2000, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[8] D. Bouros,et al. Availability of antidotes in hospital pharmacies in Greece. , 2001, Veterinary and human toxicology.
[9] S. Walton,et al. Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity , 2000, Journal of cardiovascular pharmacology and therapeutics.
[10] J. Bussières,et al. Availability of antidotes in Quebec hospitals before and after dissemination of guidelines. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] C. Morillo,et al. Congestive heart failure in Latin America: the next epidemic. , 2004, American heart journal.
[12] A. Woolf,et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. , 2000, Annals of emergency medicine.
[13] J. Brubacher,et al. Adequacy of antidote stocking in British Columbia hospitals: the 2005 Antidote Stocking Study. , 2006, CJEM.
[14] D. Jacobsen,et al. A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae , 2012, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.
[15] Nara Azevedo,et al. Inovao em vacinas no Brasil: experincia recente e constrangimentos estruturais , 2003 .
[16] J. Feussner,et al. Reassessing the efficacy of digitalis: from routine treatment to evidence-based medicine. , 2010, The American journal of the medical sciences.
[17] Viviane Midori Murata. Produção e caracterização da porção Fab do anticorpo anti-digoxina utilizando a tecnologia de phage display , 2012 .
[18] C. Steffen. The dilemma of approving antidotes. , 2007, Toxicology.
[19] V. Abbott,et al. Access in New Zealand to antidotes for accidental and intentional drug poisonings. , 2012, Journal of primary health care.
[20] P. Hauptman,et al. Digoxin use and digoxin toxicity in the post-DIG trial era. , 2006, Journal of cardiac failure.
[21] T. Wenger,et al. Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. , 1991, The American journal of cardiology.
[22] K. Wong,et al. Availability of antidotes for the treatment of acute poisoning in Queensland public hospitals. , 2010, The Australian journal of rural health.
[23] R. D. Mello. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA , 2002 .
[24] M. Silva,et al. ECONOMIC EVALUATION OF POISON CENTERS: A SYSTEMATIC REVIEW , 2012, International Journal of Technology Assessment in Health Care.
[25] J. Kalil,et al. Anti-Digoxin Fab Variants Generated by Phage Display , 2013, Molecular Biotechnology.
[26] James A. Swenberg,et al. Toxicology and Epidemiology: Improving the Science with a Framework for Combining Toxicological and Epidemiological Evidence to Establish Causal Inference , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[27] Daniel Marques Mota,et al. Perfil da mortalidade por intoxicação com medicamentos no Brasil, 1996-2005: retrato de uma década , 2012 .
[28] Amy F Wolkin,et al. Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. , 2012, Annals of emergency medicine.
[29] Silas W Smith. Drugs and pharmaceuticals: management of intoxication and antidotes , 2010, EXS.
[30] R. Gair. Antidote program in British Columbia. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[31] Fundação Nacional de Saúde. Manual de diagnóstico e tratamento de acidentes por animais peçonhentos , 1998 .
[32] A. Pankratov. [Cardiac glycosides]. , 1978, Meditsinskaia sestra.
[33] N. Buckley,et al. Oximes for acute organophosphate pesticide poisoning. , 2005, The Cochrane database of systematic reviews.
[34] S. Lowenstein,et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. , 1996, JAMA.
[35] K. Luomanmäki,et al. [Calcium channel blocker poisoning]. , 1993, Duodecim; laaketieteellinen aikakauskirja.
[36] J. Brubacher,et al. Antidote stocking in British Columbia hospitals. , 2003, CJEM.
[37] V. Cohen,et al. Antidotes for toxicological emergencies: a practical review. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[38] T. Galvão,et al. Padronização das informações toxicológicas no Brasil , 2011 .